| Identification | Back Directory | [Name]
Desvenlafaxine succinate | [CAS]
386750-22-7 | [Synonyms]
Pristiq
Unii-zb22enf0xr
WY 45233 succinate
Desvenla succinate
Desvenlafaxine succinate
Pristiq succinate hydrate
C16H25NO2.HOOCCH2CH2COOH.H2O
Desvenlafaxine (succinate hydrate)
Desvenlafaxine succinate USP/EP/BP
Desvenlafaxine succinate monohydrate
Desvenlafaxine succinic acid monohydrate
O-Desmethylvenlafaxine succinate hydrate
[2H6]-rac-O-Desmethyl Venlafaxine Succinate Hydrate
(1R)-2-(2-(diMethylaMino)-1-phenylethyl)cyclohexanol
Desvenlafaxine (O-DesMethyl Venlafaxine) Succinate Monohydrate
4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenolsuccinate
PRISTIQ SUCCINATE HYDRATE;O-DESMETHYLVENLAFAXINE SUCCINATE HYDRATE
4-(2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol succinate hydrate
4-(2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol succinate monohydrate
2-(1-Hydroxycyclohexyl)-2-(4-hydroxyphenyl)ethyl]dimethylammonium3-carboxypropanoatemonohydrate
Butanedioic acid, compd. with 4-[2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol, hydrate (1:1:1) | [Molecular Formula]
C16H25NO2.C4H6O4.H2O | [MDL Number]
MFCD09970707 | [MOL File]
386750-22-7.mol | [Molecular Weight]
399.48 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at +4°C | [solubility ]
DMSO:3.0(Max Conc. mg/mL);7.51(Max Conc. mM) | [form ]
Powder | [color ]
White to off-white | [Stability:]
Hygroscopic | [InChI]
InChI=1S/C16H25NO2.C4H6O4/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16;5-3(6)1-2-4(7)8/h6-9,15,18-19H,3-5,10-12H2,1-2H3;1-2H2,(H,5,6)(H,7,8) | [InChIKey]
ORUUBRMVQCKYHB-UHFFFAOYSA-N | [SMILES]
C(C(=O)O)CC(=O)O.C(C1C=CC(O)=CC=1)(C1(CCCCC1)O)CN(C)C |
| Hazard Information | Back Directory | [Description]
Desvenlafaxine Succinate is a dual serotonin and norepinephrine
reuptake inhibitor (SNRI) that was approved for the
treatment of major depressive disorder (MDD) in the United
States in 2008. In order to improve the efficacy and
safety profile of venlafaxine, Wyeth discovered and developed
one of the major metabolites of venlafaxine, namely the
O-desmethyl metabolite (desvenlafaxine). Desvenlafaxine is
also being developed for the treatment of moderate to severe
vasomotor symptoms associated with menopause (i.e., hot
flashes and night sweats) and is also in phase III clinical trials
to study it’s effectiveness in treating fibromyalgia and
neuropathic pain. | [Chemical Properties]
Desvenlafaxine succinate (Pristiq SR) is an extended-release tablet for oral administration that contains desvenlafaxine succinate, a structurally novel SNRI for treating MDD. Desvenlafaxine succinate is a white to off-white powder that is soluble in water. The solubility of Desvenlafaxine succinate is pH-dependent. Its octanol: aqueous system (at pH 7.0) partition coefficient is 0.21. Desvenlafaxine succinate (Pristiq SR) is available as a 50 mg extended-release tablet for oral administration. The 50 mg tablet consists of light pink, square (pyramid, one-sided), film-coated tablets debossed “W” over “50” on the flat side.
| [Uses]
Antianxiety therapeutic | [Synthesis]
Desvenlafaxine has been prepared via
two different routes, and both are described in the scheme.
The first route involved simple demethylation of venlafaxine
(67) using L-selectride in dimethoxyethane giving desvenlafaxine
68 as its free base in 91% yield. Compound
68 was then recrystallized with succinic acid in acetone/
water to give desvenlafaxine succinate (VIII) in 86%
yield. An alternative method to prepare desvenlafaxine is
described in the bottom portion of the scheme. 4-Benzyloxyphenylacetic
acid 69 was converted to its corresponding
acid chloride upon treatment with thionyl chloride and catalytic
DMF in refluxing methylene chloride. The crude
reaction mixture was added to a solution of dimethylamine
hydrochloride and triethyl amine in methylene chloride at 5
??C to give dimethylacetamide 70 in 90% yield. Deprotonation
of 70 with LHMDS in THF at -70 ??C followed by addition
of cyclohexanone gave alcohol 71 in 82% yield. Reduction
of the acetamide with borane THF complex in refluxing THF produced dimethyl amine 72 in 66% yield. Catalytic
hydrogenation in the presence of 20% Pd/C effected debenzylation
of 72 to give desvenlafaxine free base 68 in 87%
yield.
| [in vivo]
Desvenlafaxine succinate hydrate (30 mg/kg, orally) significantly increases extracellular NE levels but had no effect on DA levels using microdialysis[1]. | Animal Model: | Male rats[1]. | | Dosage: | 30 mg/kg. | | Administration: | Orally. | | Result: | Significantly increased extracellular NE levels compared with baseline in the male rat hypothalamus but had no effect on DA levels using microdialysis. |
| [storage]
Store at -20°C |
|
|